RT Journal Article
SR Electronic
T1 Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 2647
OP 2652
DO 10.21873/invivo.12083
VO 34
IS 5
A1 KAZUO KOBAYASHI
A1 YUSUKE IIKURA
A1 MAKOTO HIRAIDE
A1 TAKASHI YOKOKAWA
A1 TAKESHI AOYAMA
A1 SARI SHIKIBU
A1 KOKI HASHIMOTO
A1 KENICHI SUZUKI
A1 HITOSHI SATO
A1 ERIKA SUGIYAMA
A1 MASATAKA TAJIMA
A1 TOSHIHIRO HAMA
YR 2020
UL http://iv.iiarjournals.org/content/34/5/2647.abstract
AB Background/Aim: Immune-related adverse events (irAEs) are associated with the efficacy of immune-checkpoint inhibitors in patients with melanoma and non-small cell lung cancer. We therefore evaluated the relationship between irAEs and nivolumab efficacy against metastatic renal cell carcinoma. Patients and Methods: The medical records of 53 consecutive patients were reviewed and analyzed. Results: Median overall survival was significantly better in patients who showed irAEs at any time compared to patients without irAEs (p=0.013). We identified irAEs in 24 of 53 patients (45.3%), including four patients (7.5%) with grade 3 events. Multivariate analysis also revealed that risk factors for the onset of irAEs were positively associated with a platelet-to-lymphocyte ratio <156 before nivolumab treatment (p=0.006). Conclusion: Development of irAEs was associated with survival outcomes of nivolumab treated patients with metastatic renal cell carcinoma.